{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"24"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"294"},{"groupId":"OG001","value":"144"}],"units":"Participants"}],"description":"Endoscopic-histologic mucosal improvement defined as an absolute endoscopic subscore of 0 or 1 point from modified Mayo score and an absolute RHI score of 3 points or less with an accompanying lamina propria neutrophils and neutrophils in epithelium subscore of 0 point. Patients with dose adjustment to CT-P13 SC 240 mg prior to Week 54 were considered as endoscopic-histologic mucosal improvement not achieved.","groups":[{"description":"CT-P13 SC 120 mg","id":"OG000","title":"CT-P13 SC 120 mg"},{"description":"Placebo","id":"OG001","title":"Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All-randomized population","reportingStatus":"POSTED","timeFrame":"Week 54","title":"Percentage of Patients Achieving Endoscopic-Histologic Mucosal Improvement at Week 54","type":"SECONDARY","unitOfMeasure":"Participants"}